EUVIMEDEUVIMED entdecken
Crossref

Results of adjunctive homogenate amniotic membrane eye drops in the management of refractory ocular surface disease with dry eye manifestations

Erika Bonacci, Adriano Fasolo, Ettore Biondan, Diletta Trojan, Stefano Ferrari, Giulia Montagner, Stefano Barabino, Antonio Di Zazzo, Emilio Pedrotti

International Ophthalmology · 11.06.2026 · 46 (1)

DOI: 10.1007/s10792-026-04137-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Ophthalmology, online erschienen am 11.06.2026. Verfasst von Erika Bonacci und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Engineering for Innovation Medicine - Ophthalmology Clinic, University of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Amnion, Dry Eye Syndromes. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate clinical outcomes of adjunctive treatment with homogenate human amniotic membrane eye drops (AMED) in patients with refractory ocular surface disease with dry eye (DE) manifestations.

Methods

We retrospectively reviewed patients’ medical records, ocular surface images, and instrumental data related to Schirmer I test, Oxford and Efron grading, non-invasive tear break-up time, Ocular Surface Disease Index (OSDI), adverse events, and symptom recurrence after discontinuation. All patients were assessed for safety while the efficacy analysis included patients who completed 2-month uninterrupted AMED treatment, without modification of topical or systemic therapy in the previous two months or during the treatment period.

Results

A total of 160 patients were exposed to AMED. Twenty-three (14.4%) patients discontinued treatment and 25 (15.6%) showed adverse events. 112 (70%) patients [mean (SD) age 57 (16) years], 73.0% female, were included in the efficacy analysis. We observed improvement in corneal Oxford grading in graft-versus-host disease (GVHD) and limbal stem cell deficiency (LSCD) patients (P < 0.001 and P = 0.02, respectively) and conjunctival Oxford grading in GVHD, LSCD, Sjögren’s syndrome (SS) and non-Sjögren’s dry eye (NSDE) (P < 0.001); decreasing in Efron score in GVHD and SS (P < 0.001 and P = 0.03, respectively). Tear film stability improved across almost all groups and OSDI showed clinically modest changes. Symptoms recurrence was reported in 86.9% of patients within one month after AMED discontinuation without adverse events reported during 2-month continuous treatment.

Conclusions

Adjunctive AMED treatment was associated with objective improvements of ocular surface, with limited effects on symptoms, likely reflecting the multifactorial nature of DE manifestations across clinically and pathophysiological distinct entities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmnionDry Eye SyndromesAdultAgedFemaleHumansMaleMiddle AgedFollow-Up StudiesLimbal Stem Cell DeficiencyOphthalmic SolutionsRetrospective StudiesTearsTreatment OutcomeGraft vs Host DiseaseSjogren's Syndrome

Stichwörter der Autor:innen

Dry eye diseaseHomogenate amniotic membrane eye dropHuman amniotic membraneOcular surface disease

Substanzen

Ophthalmic Solutions

Autor:innen und Institutionen

  • Department of Engineering for Innovation Medicine - Ophthalmology Clinic, University of Verona, Verona, Italy.
  • Department of Surgery, Dentistry, Maternity and Infant - Ophthalmology Clinic, University of Verona, Verona, Italy. adriano.fasolo@yahoo.it.
  • Research Unit, The Veneto Eye Bank Foundation, Venice, Italy. adriano.fasolo@yahoo.it.
  • Ospedale Policlinico G.B. Rossi, P. Le L. A. Scuro 10, 37134, Verona, Italy. adriano.fasolo@yahoo.it.
  • Department of Surgery, Dentistry, Maternity and Infant - Ophthalmology Clinic, University of Verona, Verona, Italy.
  • Research Unit, Veneto Tissue Bank Foundation, Treviso, Italy.

Zitieren

APA

Bonacci, E., Fasolo, A., Biondan, E., Trojan, D., Ferrari, S., Montagner, G., Barabino, S., Di Zazzo, A., & Pedrotti, E. (2026). Results of adjunctive homogenate amniotic membrane eye drops in the management of refractory ocular surface disease with dry eye manifestations. International Ophthalmology, 46(1). https://doi.org/10.1007/s10792-026-04137-0

Vancouver

Bonacci E, Fasolo A, Biondan E, Trojan D, Ferrari S, Montagner G, et al. Results of adjunctive homogenate amniotic membrane eye drops in the management of refractory ocular surface disease with dry eye manifestations. International Ophthalmology. 2026;46(1). doi:10.1007/s10792-026-04137-0

BibTeX
@article{Bonacci2026,
  author = {Bonacci, Erika and Fasolo, Adriano and Biondan, Ettore and Trojan, Diletta and Ferrari, Stefano and Montagner, Giulia and Barabino, Stefano and Di Zazzo, Antonio and Pedrotti, Emilio},
  title = {Results of adjunctive homogenate amniotic membrane eye drops in the management of refractory ocular surface disease with dry eye manifestations},
  journal = {International Ophthalmology},
  year = {2026},
  volume = {46},
  number = {1},
  doi = {10.1007/s10792-026-04137-0}
}
Kostenlos starten →